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SPOl THE MANAGEMENT OFFAMILIAL
OVARIAN CANCER, J. Mackay, University of
Cambridge, Department ofClinical Oncology, Addenbrooke's
Hospital, Cambridge CB2 2QQ.
The recent identification of two of the genes involved in
familial breast and ovarian cancer has generated widespread media
interest. This has resulted in unrealistic expectations from both the
public and the medical profession as to the ease and likely availability
of genetic testing to predict cancer susceptibility. In reality, these
recent findings will have direct relevance to only a small number of
individuals with afamily history ofovarian cancer.
A strategy for the management of those presenting with a
family history of ovarian cancer will be presented. This strategy
allows stratification into high risk, moderate risk and low risk
groups. Those considered at high risk are offered BRCA1 testing.
The important clinical messages to convey to those wishing to
embark on BRCA1 testing will be outlined, emphasising many of the
commonly held misconceptions.
Those at moderate risk are offered regular screening. A study
of regular screening with annual ultrasound and CA125 estimation
for those at significantly increased risk offamilial ovarian cancer will
be described.
The implications, possible drawbacks and potential problems
inherent in this management policy will be considered.
SP03 TREATMENT OF EARLY OVARIAN CANCER
S. Pecorelli, European Institute ofOncology,
Milan, Italy
Ovarian cancer is the fifth leading cause ofdeath in women in the USA and the
most common cause ofdeath in women with gynaecological malignancies in
most westem countries. Ofthe ovarian cancers, 85-90% are epithelial and more
thattwo-third are stage III and IV. Comprehensive surgical staging enables the
selection ofappropriate additional therapy, provides information to determine
prognosis and offers the patientthe best chance for cure. As no randomised trials
on the primary surgical management have been performed, only an indirect
indication ofits impact can be given. In the past, several randomised trials have
been performed to test the value ofadjuvant therapies following surgery in early
stage disease. The majority ofthese suffered from a number ofshort comings,
i.e. omission ofa therapy-free arm in the high-risk early disease stages, inclusion
ofborderline tumours, incomplete surgical staging or inclusion ofpatients with
stage II or III with minimal residual disease. More recent trials indicated that
when comprehensive surgical staging is performed, patients with well
differentiated or moderately differentiated cancer confined tothe ovaries (stages
IA and IB) do not need any additional therapy. Non-randomised studies using
comprehensive surgery in stage I-IIA grade I patients confirmed this and also
suggested that patients who wished to retain their reproductive function could
even qualify for conservative surgery. In all other early stage disease cases with
less favourable features, the situation is less clear since randomised trials have
not included a no-treatment control arm. In patients with grade 3 stage I tumours
or with cancer outside the ovaries but limited to the pelvis (stage II) or with clear
cell carcinoma, the recommendation in the US is to use adjuvant therapy. At
present, it is generally believed in the US that chemotherapy is preferable to
radiotherapy or i.p. 32P. In Europe, some studies evaluating the role ofadjuvant
therapy in early ovarian cancer patients did not show an overall survival benefit
for those treated in the adjuvant setting versus those treated on relapse. From
retrospective reviews ofstage I ovarian cancer patients, some investigators have
questioned the value ofadjuvant chemotherapy.
SP02
SURGICAL INTERVENTION IN OVARIAN CANCER
Ian Jacobs, Consultant Gynaecological Oncologist, St Bartholomew's
and The Royal London Hospitals
Surgery isthe 10 procedure for diagnosis, staging andtherapy of
ovarian cancer and is likelyto remain so forthe forseeable future.
Prevention: Oophorectomy isjustified forhigh risk individuals
following counselling and assessment (+/- mutation screening).
Primary Surgery: Forpatientswith apparently early stage disease
thorough staging is crucial as occult metastasishasbeen well
documented. Ifprimary surgery does not include careful staging,
understaging may lead to under treatment. In advanced disease the
principle aim ofsurgery is cytoreduction to remove allmacroscopic
disease. The evidence base forthisislimited, as it is derived from
retrospective studies showing improved survival inpatientswho have
undergone successful cytoreduction compared to patients for whom
cytoreduction was not achieved.
Interval Debulking Surgery: A randomised trial ofinterval
debulking surgery after 3 cycles ofchemotherapy was reportedbythe
EORTC in 1995 and revealed an increased median survival in the
surgical group (26 vs 20 months). Studies are in progress to confirm
this data which could have a major impact on clinical practice.
Secondary surgery: Second lookprocedures to assess response to
chemotherapyhave not been shown to influence survival. Secondary
debulkingprocedures are onlyjustified in carefillly selected cases.
Palliative surgery: Palliative surgery is considered for bowel
obstruction which does not respond to conservative measures. The
morbidityishigh and mean survivalpost surgery is short but quality of
life mavbe imuroved in carefitllv selected cases.
SP04 CHEMOTHERAPY FOR EPITHELIAL
OVARIAN CANCER (EOC), M. E. Gore,
Royal Marsden Hospital, London
Patients with EOC have a 5 year survival of 20%. The reason
the overall survival is so poor is that 70-80% ofpatients present
with advanced disease. Patients with early disease can be sub-
divided into those in whom adjuvant chemotherapy following
surgery is probably not required (Stage Ia, Ib, grade 1-2), those
with a definite indication for adjuvant chemotherapy (Stage II)
and an intermediate group where the place of adjuvant
chemotherapy is less certain (Stage Ic, clear cell histology,
grade 3). Platinum-based chemotherapy forms the mainstay of
all regimens and overview analyses as well as a number of
individual randomised trials have suggested a benefit for
combination platinum-based therapy. The results of ICON 2
may alter this latter view. A pragmatic approach is to treat
patients who are elderly or have a poor performance status
with single agent carboplatin and those in whom cure or long
term survival is a possibility, with combination therapy. In the
US platinum-paclitaxel is regarded as the standard regimen
consequent on the results of GOG Protocol No. 111. A very
important follow up intergroup study is to be reported in 1997.
Patients with relapsed disease are incurable although those who
relapse with a treatment-free interval of > 1 year have a good
chance of a further response to platinum-based chemotherapy.
More commonly, patients relapse within 12 months and
although a number ofnew agents have demonstrated activity in
this situation, response rates are 15-20% and remissions are
short. Two reports suggest higher response rates with
platinum-based combinations in this difficult group.8 Invited Oral Presentations
SP05 CHEMOTHERAPY AS PALLIATIVE TREATMENT FOR
PATIENTS WITH ADVANCED EPITHELIAL OVARIAN
CANCER Paul A Vasey CRC Department of Medical Oncology,
University of Glasgow, Garscube Estate, Switchback Road, Bearsden,
Glasgow, G61 IBD.
Despite demonstrating initial response rates of 60-80% with selected
platinum-based regimens, around three-quarters of patients
presenting with advanced epithelial ovarian cancer are not cured,
and eventually require a salvage regimen for palliation of symptoms.
As there is no convincing evidence that any salvage regimen is
curative, it is appropriate, when considering the therapeutic options,
to focus not only on survival endpoints, but also on quality of life,
delaying time to tumour progression, and to delaying the onset of
symptoms. In addition, patients requiring salvage chemotherapy are
often of poorer performance status, and mO,ay have residual side-
effects from initial treatment protocols. Regimens which therefore
involve a low risk of toxicity and treatment-related morbidity become
more attractive. It is generally accepted that patients with a long
treatment-free period following first-line platinum therapy have an
excellent chance of re-responding following further treatment with
platinum. However, although this does provide good palliation of
symptoms, such responses are usually relatively brief. Patients with
platinum-refractory disease offer new challenges to find agents which
are both active and well tolerated. The most promising new groups of
drugs, the taxoids and topoisomerase inhibitors are associated with
significant toxicities, which although may be acceptable in younger,
fitter patients, are unlikely to be well tolerated in more elderly patients
or patients with significant co-morbid conditions. There are, however,
established cytotoxic agents possessing activity in platinum-refractory
patients which have relatively few toxicities and the considerable
advantage of oral administration. These agents include Treosulphan,
hexamethylmelamine, chlorambicil, etoposide and Tamoxifen, and
their role in the palliation of patients with ovarian cancer will be
discussed.
SP07 ROLE OF THE UKCCCR, P.R. Twentyman,
UKCCCR, PO Box 123, Lincoln's Inn Fields, London WC2A 3PX
The United Kingdom Coordinating Committee on Cancer Research
(UKCCCR) provides a forum for the coordination of research
activities between the main cancer research funding bodies in the
UK (ie the CRC, ICRF and MRC). A major task is the facilitation
of national and international cancer clinical trials and other multi-
centre studies in the UK. Amongst current UKCCCR trials are the
QUASAR trial of chemotherapy in colorectal cancer, the 'Age' and
'Frequency' trials in breast cancer screening, and the 'Aim High'
trial of alpha interferon in melanoma. Each trial steering group
reports to one of the UKCCCR site-specific subcommittees which
in turn report to the Trials Committee (Chairman, Prof Nick
Thatcher)
When a proposed clinical trial comes to the attention of the
UKCCCR it is initially prioritised by the Trials Committee. If it
appears that joint funding by two or more of the funding bodies is
appropriate, then a 'lead' funding body is identified. This body will
then carry out peer review ofthe proposal on behalfof itself and the
other involved funding bodies. In parallel with this, the UKCCCR
Secretariat will organise detailed protocol review. At the end of the
day, however, each individual funding body makes its own decision
regarding the priority for a given proposal and the funding to be
awarded.
The MRC has recently introduced a system whereby trial 'outlines'
are judged at a very early stage. For those proposals which pass this
stage, the NHS R&D are then informed about the trial in order that
appropriate service costs can be earmarked should the trial be
funded. The precise way whereby UKCCCR trials can slot into this
system is currently under discussion.
SP06 FUNDING OF TRIALS WITHIN THENHS, R. J.
Lilford, Dept ofHealth, NHS Executive, West Midlands,
Birmingham B16 9PA.
I shall discuss the duties ofthe NHS Clinical Trials Advisor.
These are:
1. To assist inthe development ofpolicy concerned with the excess treatment
costs ofnon-commercial clinical trials, andto implement the same. This work
has focused on an interim solution to this difficult problem, and to input to a
definitive solution following the consultation exercise. Excess treatment costs
should be met from normal contracting procedures, but a subvention will be
available in certain selected cases where these costs are considerable, and
inequitably spread around the service. Trials involving screening are a
particular issue. I will discuss the restricted conditions underwhich a
subvention may be used.
2. interaction with industry and otherbodies. The difference between treatment
and service costs is a current importance issue for discussion between the
Department ofHealth and the MRC, and I am also assisting the MRC in
their work on defining good clinical practice guidelines forthe conduct of
clinical trials.
3. the development ofpolicy regarding the methodology ofclinical trials. In this
work, I am supported by a small clinical trials policy support unit, within
The University ofBirmingham and Wessex Institute. This unit considers the
policy options which might arise from developments in methodology. For
example, there are arguments forthe greater and more explicit use of
modelling at the design stage ofclinical trials. In addition, there are
arguments for the use ofclinical trials offices to oversee clinical trials in
Trusts. I shall describe this work in more detail.
SP08 CANCER TRIALS -
IS THE FUNDING SYSTEM WORKING?
J R Yarnold, Academic Radiotherapy Unit, The Royal Marsden
NHS Trust, Downs Road, Sutton, Surrey. SM2 5PT.
Recommendations based on the Culyer Report for NHS support of
clinical trials will be implemented in April 1998. Costs will be shared
between the funding agencies, hospital trusts and purchasers. Costs of
trial coordination and analysis etc. ('direct costs') will be met by the
funding agencies. The costs of an experimental treatment e.g. drug
costs, that will be borne by the NHS if it subsequently becomes part of
standard care ('treatment costs') will be met purchasers. Costs to
hospitals of consent procedures, additional investigations and data
collection ('service support costs') are met by the R&D levy
(approximately £350 million) disbursed by the DoH to Trusts involved
in nationally approved clinical research protocols.
This system offers a rational framework forfunding NHS R&D, but the
funding available is very small in relation to R&D priorities and to total
NHS expenditure (>£40 billion). There are problems, the first of which
is the lack ofnationally agreed priorities for breast cancer trials research
among the funding agencies. Divergent priorities strengthen the need for
an effective United Kingdom Coordinating Committee on Cancer
Research (UKCCCR), but make its task more difficult. Purchasers may
not agree to pay the treatment costs ofexpensive drugs. Trusts in receipt
of service support funding may not bother to target it at research-active
clinicians.Invited Oral Presentations 9
SP09 THE MOLECULAR BASIS OF DNA REPAIR
SYNDROMES, J.H.J. Hoeijmakers, MGC
Department of Cell Biology & Genetics, Erasmus University, PO
Box 1738, 3000 DR Rotterdam, The Netherlands
All organisms have evolved an intricate network of
complementary DNA repair systems, to cope with DNA damage
induced by endogenous or exogenous genotoxic agents These
systems are crucial to ensure genetic stability and prevent
mutagenesis and carcinogenesis. Defects in DNA repair result in
hypersensitivity to genotoxic agents and carcinogenesis.
The nucleotide excision repair (NER) pathway for
elimination ofUV-induced lesions is understood in great detail and
is associated with three clinically and genetically heterogeneous
human syndromes characterized by marked sun sensitivity:
xeroderma pigmentosum (XP), Cockayne syndrome (CS) and
trichothiodystrophy (TTD). XP patients show an over 100Ox
increased risk of skin cancer, in contrast to CS and TTD. The
latter disorders display severe developmental abnormalities and
neurodysfunction. In addition TTD is characterized by sulphur-
deficient brittle hair and nails, due to a reduced synthesis of
cysteine-rich matrix proteins. At least 10 genes are involved,
virtually all of which have been cloned. Some of the encoded
proteins appeared also implicated in other cellular processes,
explaining puzzling clinical features associated with defects inthese
genes. The proteins defective in TTD and in 2 of the
complementation groups withcombined XP/CS reside in the TFIIH
complex, involved in basal transcription and in NER. Many of the
CS and TTD features may be due to a crippled TFIIH transcription
function, affecting the expression of a specific set of genes. To
understand the complex genotype-phenotype relationship we have
generated mouse models by gene targeting inembryonal stem cells.
The present knowledge of the mechanism and biological impact of
this and other damage repair pathways will be summarized.
spi1
THE p53 RESPONSE TO IONISING RADIATION IN
ADULT AND DEVELOPING TISSUES
Peter A Hall, Department of Molecular & Cellular Pathology,
University ofDundee, Dundee.
The induction of the p53 response to ionising radiation has been
studied during murine development and in the adult animal. The
response has been assessed by precise quantitative assay of p53
protein levels in tissues and by immunohistochemistry. Newly
developed transgenic mice in which a lacZ transgene is driven
by a p53 response element have also been used to directly assess
the transcriptional activity of the induced protein. There is
striking developmental control of the p53 response so that in
early development all tissues accumulate high levels of p53
following radiation and indeed p53 is present at elevated levels
in some unirradiated tissues. Later in development clear
heterogeneity of the p53 response becomes apparent, both in
terms of the responses of individual tissues and of cell
populations within those tissues. The study of lacZ transgene
expression and the occurrence of apoptosis in different tissues
that accumulate p53 protein point to a further level of control
regulating the nature and degree of the downstream response to
elevated levels of p53 in cells. These findings have important
implications for the susceptibility of different tissue types to
carcinogenic and other insults. The early expression of the p53
response is consistent with novel models of p53 function that
suggest it may have evolved principally as a defence against
teratogenic insult that permits plasticity of development.
SP1 0 GENOMIC INSTABILITY, Eric G Wright,
Radiation and Genome Stability Unit, Medical
Research Council, Harwell, Oxfordshire OX1 1 ORD, UK.
The biological consequences of exposure to genotoxic agents include
gene mutation, chromosome aberrations, cellular transformation and cell
death. These effects are attributed to irreversible changes fixed during
DNA replication or during the processing of the DNA damage by
enzymatic repair processes. Accordingly, it has been generally accepted
that most of these changes take place during the cell cycles immediately
following exposure. Genomic instability may arise as a consequence of
mutational changes in genes, the products of which are involved in
recognising, responding to or repairing DNA damage. However, evidence
is rapidly accumulating that apparently normal cells that have survived
genotoxic insults may produce descendants in which a high frequency of
de novo chromosome aberrations and gene mutations arise or in which
there is an enhanced death rate. These delayed effects are manifestations
of an induced genomic instability, a phenotype induced at frequencies
considerably greater than conventional mutation frequencies. At present
little is understood of the processes involved in the initiation of inducible
instabilities and in the maintenance and transmission of the phenotype
over many generations of cell replication. Furthermore, there is no reason
to suppose that all the various end points are necessarily attributable to a
common mechanism. To date, genomic instability induced by ionizing
radiation has been more extensively studied than instability induced by
chemical agents and it is becoming evident that the expression of inducible
instability has a strong dependence on the type of radiation exposure, the
cell type irradiated and the genetic "predisposition" of the irradiated cell.
SP1 2 Replacing suppressor gene function with small
synthetic molecules - therapeutic opportunities. D.P.Lane, Ted
Hupp, Steve Picksley, Alison Sparks, Robin Fahraeus, Jesus
Paramio, Sonia Lain, Kathryn Ball. Cancer Research Campaign
Laboratories and Department of Cellular and Molecular Pathology,
University ofDundee, Scotland.
Loss of suppressor gene function occurs frequently in human
cancers. Concentrating on the p53, p16 and p21, we have sought to
identify small molecules that can regulate the activity of these cell
cycle regulatory proteins and to create synthetic tumour suppressor
proteins. A detailed biochemical analysis of the p53 tumour
suppressor protein has established that it is produced in a latent
inactive form that is activated for DNA binding by modification of a
negative regulatory domain at the C terminus of the protein. Direct
microinjection of anti-C terminal activating antibodies has been
shown to activate the transcriptional function of wild type and
mutant p53 in vivo establishing the potential therapeutic capability
of such activators. We have designed synthetic suppressor proteins
by localising the kinase inhibitory domain of the p16 and p21
proteins. Synthetic peptides containing these domains linked to
transport peptide sequences have been prepared. The complete 36
amino acid synthetic mini proteins are taken up from the tissue
culture medium and is able to block cell cycle progression. These
approaches not only provide novel insight into protein-protein
interactions involved in suppressor gene function, but are also
leading directly to the design and discovery of novel anti cancer
treatments.10 Invited Oral Presentations
SP13 PRINCIPLES CF DEVELOPMENT? L.Wfolpert, Dept.
of Anatomy & Devel.Biology, University
Col leqe London,London,UK
We have a quite good understanding of the mechanisms
of animal embryonic development particularly frnm studies
of the fruit fly Drosophila. Similar mechanisms to those
in Drosophila devel6opment are also present in vertebrates.
Evolution seems to have been lazy: once a suitable
mechanism was discovered it was used aaain and again with
modifications. Axes for embryonic patternino are commonly
Cartesian. In Drosophila they are already laid down in the
egg but in mammals they involve cell interactions. Once
the axes are established patterning of the embryo takes
place by tvwo main mechanisms, asymmetric cell divisions
and positional information. Combinations of transcription
factors can activate gene expression at very specific
regions in a modular fashion - the pair rule stripes in
Drosophila providing an excellent example. In Xenopus
there is evidence for genes being activated at threshold
concentrations of positional signals. Changes in form,
morphogenesis, like gastrulation and neurulation is a
result of forces generated by the cells at specific
locations. Convergent extension, a key feature of
gastrulation, is only partly understood. It is hard to
find general principles for cell differentiation which is
the result of different combinations of transcription
factors, muscle different-iation providing a aood example.
Growth is pronrammed early in development but is poorly
understood. The best example is the control of the pattern
of cell division in the early Drosophila embryo.
Wolpert, L. (1994) Do We Understand Development?
Science, vol.266, 28 October
SP15 MATHEMATICS OF COMPLEX SYSTEMS,
J.A. Sherrattt, A.J. Perumpanani2, and J. Norbury2.
tMathematics Institute, University of Warwick,
Coventry CV4 7AL. 2 Mathematical Institute,
24-29 St Giles', Oxford OX1 3LB.-
The twin revolutions in molecular biology and nonlinear mathematics
generate a wide range of exciting opportunities for the application of the
mathematics to oncology. In particular, theoretical models can act as
a link between data and hypotheses at the cellular and molecular level,
and macroscopic observations. The mathematics of complex systems
provides a toolkit which enables the implications of nonlinear interac-
tions within a single cell, or in biochemical interactions between cells,
to be studied. I will discuss briefly a number of examples of modelling
studies, focussing in particular on a theoretical model of matrix degra-
dation during tumour invasion. Protease production and altered cell
motility are key components of the invasive phenotype; I will describe
a model enabling their interplay to be studied in detail. The model
uncovers a number of new biological results, in particular suggesting a
novel mechanism for the parabolic dependence of invasion on protease
production. I will conclude by summarising the current applications and
future potential for nonlinear mathematical modelling of cancer biology.
SP14 Mathematics on a Sunday afternoon in Scotlandl
M Baum ChM FRCS
Department of Surgery, University College London,
67-73 Riding House Street, London WI P 7LD
The management of cancer is based on conceptual models we have
of the disease. From time to time these models must approximate to
reality as judged by the therapeutic successes. However these
therapeutic successes have been most marked in the management of
childhood cancer the leukemia's and lymphomas. Successes in the
management of solid tumours have been much more modest.
Therefore we should acknowledge that our conceptual frameworks
which determine our treatments are seriously flawed. Models of
cancer can either be biological or mathematical. The biological models
are more familiar and often appear as schematic diagrams in text
books of tumour biology. However mathematical modelling is less
familiar to the clinical oncologist. The simplest examples of
mathematical modelling are those originally described by Skipper,
upon which the rationale of cyclical chemotherapy is based. In other
words we conceptualise that metastases grow according to
logrhythmic or Gompertzian functions and that each cycle of
chemotherapy is responsible for log cell kill. It will be the purpose of
this presentation to illustrate how flawed this approach must be and
how the description of breast cancer survival as hazard rates with time
illustrates the bankruptcy of the conventional paradigm. To replace
this model will present as an example a new paradigm that describes
breast cancer and micrometastases as complex organisms in a state
of dynamic equilibrium existing close to a chaotic boundary. will
advocate new mathematical approaches to explore these concepts
and also the inevitable therapeutic sequelae of such a conceptual
revolution.
1. Skipper, H.E. (1967) Criteria associated with destruction of
Leukaemia & solid tumours cells in animals. Cancer Res; 27: 2636
SP1 6 NON-LINEAR MATHEMATICS: ITS POTENTIAL USE IN
THE MANAGEMENT OF CANCER,
A. Dalgleish' and Paul Goddard2, 'Division ofOncology, St Georges Hospital Medical
School,2Department of Clinical Radiology, Bristol Royal Infirmary.
Biology systems are extremely complex and cannot be satisfactorily evaluated with linear
mathematics. This is even more so for analysing disorder ofcomplex systems or disease. Time
series analysis using chaos mathematics may be a more appropriate method ofprediction of
incidence ofinfection ofmalignancy and response ofa population to treatment and the
application ofnon-linear mathematics to individual patients with a complex disease such as
cancer, may help determine which patients will develop metastatic disease and/or a local
recurrence.
The morphogenesis oftissues in embryo, wound healing and the growth patterns ofneoplasia
can already be modelled mathematically and complex medical images from both pathology and
radiology, can be analysed by determining fractal dimensions andpatterns.
In a chaotic system the unpredictable behaviour arises because ofminute variations in the
starting conditions which are amplified in a non-linear manner, such that it is never possible to
exactly repeat the sequence. Within such chaos, trends can appear which are known as
attractors and these attractors can create order and measures ofcomplexity out ofthe chaos. For
example, correlations between different prognostic indicators for tumour development will
emerge from chaotic data by the lure ofthe attractor.
Even starting with a few simple variables in order to model tumour spread the progression ofa
mutant cell within a primary is remarkably unpredictable and similar to thepatterns obtained
when trying to model and forecast weather systems. The mathematics involved in modeling
secondary spread are likely to be distinct from those ofthe primary in that thepatterns of
growth are different being gomperzian in the primary, and gradual growth probably reflecting
the establishment ofneo-angiogenesis in the secondary, which undergoes a late growth spurt
once angiogenesis has been achieved. Nevertheless the chaos inherent in the state of
malignancy forms patterns or followsan attractorandthat modelingoftherelevant variables
may result in greater understanding ofhowa tumour type will behave hence a better
understanding ofwhat should constitute appropriate preventative treatment. Neural networks
and non-linear modeling have been used in a prediction and prognosis ofbreast cancer showing
that survival curves can be produced for individual patients with a greater predictive power
than conventional techniques such as Cox's proportional hazard model.
Itis remarkable that the application ofthese techniques to complex pathology such as cancer
are onlyjust now being attempted. It is important to be aware that as well as the complexity
and chaos that can result from a very simple reiteration, the converse is also often also true in
that simplicity in nature is often generated from chaos and complexity in that this probably
represents the action ofextemal constraints. Indeed, systems are interactive and co-involve in a
manner that changes both leading to a growth ofcomplexity from simple beginnings, yet
leading to a complexity that is unpredictable in detail but whose general course is
comprehensible and predictable and it is this that would be a tremendous advance to the
management ofcancer, ifthese principles could be applied in the clinical situation.SP17 MOLECULAR BIOLOGY AND CYTOGENETICS
IN THE DIAGNOSIS OF SARCOMAS, C.S.
Cooper, Institute of Cancer Research, Haddow Laboratories,
Cotswold Road, Sutton, Surrey, SM2 5NG.
Human soft tissue and bone sarcomas account for about
3%/o of cancer deaths overall and 15% of cancers in children.
One of the most interesting genetic features of human sarcomas
has been the identification in cytogenetic studies of specific
chromosomal translocations in selected tumour categories.
Work in our laboratory has focused on the
t(X;18)(pl1.2;q11.2) translocation found in synovial sarcoma and
the t(9;22)(q23-31;,qq11-12) translocation found in myxoid
chondrosarcoma. Molecular analyses have shown that the
t(X;18) translocation can result in fusion ofthe SYTgene located
on chromosome 18 to either of two closely related genes
designated SSXI and SSX2 located on Xp11.2. The normal
function of the SYT and SSX genes are currently unknown
although homology searches have demonstrated that the N-
terminal domain of the SSX protein contain a KRAB
transcriptional repressor domain. The SYT-SSXI and SYT-
SSX2 gene fusions result in the production of SYT-SSX1 and
SYT-SSX2 hybrid transcripts that in turn enicode chimaeric
proteins in which almost the entire SYT protein is attached to the
C-terminus ofthe SSX protein.
By comparison the t(9;22) chromosome translocation in
chondrosarcomas result in the fusion of the Ewings sarcomas
EWS gene on chromosome 22 to a new steroid-thyroid receptor
gene designated CHN. As a consequence of this fusion the N-
terminal domain of EWS becomes fused to the entire CHN
steroid-thyroid receptor protein. The possible use of these
fusions and offusions found in other classes of sarcomas will be
discussed. I thank the Cancer Research Campaign UK for
supporting these studies.
SPi 9 ROLE OF RADIOTHERAPY IN THE TREATMENT
OF SARCOMAS, O.S. Nielsen, Department of
Oncology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.
Significant progress has been made in the management of patients
with sarcomas. Importantly the necessity of treatment planning
within the framework of a multidisciplinary approach has been
acknowledged by an increasing number of sarcoma centres. Local
treatment is still of utmost importance for cure of sarcomas. In
soft tissue sarcomas the treatment has shifted from radical to
more extremity saving procedures by the use of combined surgery
and adjuvant radiotherapy, thereby improving the functional
outcome and probably also quality of life. However, the optimal
timing of radiotherapy has not been settled, ie. preoperative or
postoperative radiotherapy. Neither has the role of brachytherapy
and intraoperative radiotherapy been defined. The dose given are
normally within the range 50-60 Gy in 25-30 fractions, whereas
the need for an additional boost has not been documented. Higher
doses may increase local control but also morbidity. The effect of
hyperfractionated and accelerated radiotherapy is under investi-
gation. A continuing series of technical developments have been
introduced that permit the use of progressively smaller treatment
volumes. In most studies the local failure rate has been 5-20%. A
number of predictive factors for local control have been defined
and new factors are under investigation such as Tpot, SF2, p53
and hypoxic fraction. In Ewing's sarcomas the use of surgery has
increased during the past years. However, radiotherapy remains as
effective as surgery especially in non-bulky and chemoresponsive
tumours and further improvement seems possible by better timing
of radiotherapy and surgery. In conclusion, radiotherapy still has a
definite role within the field of sarcomas, but more clinical trials
defining its optimal use and its timing in relation to surgery and
chemotherapy are unequivocally needed.
SP20 THE CHEMOTHERAPY OF SOFT TISSUE
SARCOMA I. Judson, Sarcoma Unit, Royal
Marsden NHS Trust, London, SW3 6JJ
Adult soft tissue sarcomas are a heterogeneous group of rare diseases
with a wide range of clinical and biological behaviour. High grade
tumours metastasise in 40-50% ofpatients, a risk which increases with
tumour size. Chemotherapy is used for the palliation of recurrent or
metastatic disease but its value is limited by the paucity ofactive agents.
Doxorubicin, ifosfamide and dacarbazine are the only drugs with single
agent first line response rates >10%. There is clear evidence for a dose-
response relationship for doxorubicin and ifosfamide. Dose escalation
studies have been performed, with or without haemopoietic growth
factors, giving phase II response rates as high as 45% with ifosfamide 5
g/m2 and doxorubicin 75 mg/M2 plus GM-CSF (Steward et al J Clin
Oncol 1993;11:15). However, randomised trials have yet to demonstrate
a benefit for more intensive reginmens. A dose threshold for response
may explain the failure of drug combinations to improve results
significantly (Santoro et al J Clin Oncol 1995;13:1537). High dose
ifosfamide at doses of 12-16 g/m2 is probably more active but causes
problems with neuro- and nephrotoxicity. In addition to falling
glomerular filtration, patients are at risk from a tubular leak problem
which seems to be related to cumulative dose (Le Cesne et al J Clin
Oncol 1995;13:1600). Neurotoxicity may be prevented or ameliorated
by the use of methylene blue (Kupfer et al Lancet 1994;343:763).
Although individual adjuvant studies have not shown a survival benefit,
a meta-analysis performed by the MRC has demonstrated a highly
significant improvement in relapse-free survival, both for local disease
and metastases. A trend for improved overall survival is not statistically
significant (Tierney et alBr J Cancer 1995;72:469). The challenge is to
overcome resistance to chemotherapy and identify active new agents in
the hope that improvements in the treatment of metastatic disease will
translate into truly worthwhile adjuvant therapy.
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SP21 FROM BENCH TO BED, AND BACK:
MODERN NEW DRUG DEVELOPMENT, J.
Verweij, Dept. of Medical Oncology, Rotterdam Cancer
Institute (Daniel den Hoed Kliniek) and University Hospital,
3075 EA Rotterdam, The Netherlands.
New drug development has changed considerably from
accidental findings to rational design. Whereas in particular
the limited predictability of preclinical models on the clinical
antitumor activity had initially led to scepticism on each
others research potentials, in the past decade new drug
development has more and more evolved into a close
collaboration between basic and clinical researchers.
Increasingly, the flow of obtained information is going back
and forth, stimulating further research at both sides. This is
also induced by the short periods of patency-protection,
necessitating the shortest possible development time. There
are now some nice examples of how this system should
function appropriately. The development of some
topoisomerase inhibitors, although still not completely
optimal, is such an example. With new drugs emerging on the
horizon, such as the matrix metalloprotein-inhibitors and
angiogenes-inhibitors, with completely new mechanisms of
action and a high likelihood that they will not induce
regression of visible tumors in man, it becomes inevitable that
preclinical data will have to guide clinical decisions, and that
clinical data indicating necessity of refinements will stimulate
further preclinical research. New drug development should be
strategic and stepwise, with decisions being based on facts.
Examples will be highlighted.
SP23 LUNG CANCER IN THE NORTH OF NG uars R dfiatv u Unt
ellilc6josprfi , oYok Vo'ab,
Regional Cancer Registry data from the
Yorkshire Cancer Organisation is now complete
for a population of 4 million 1976 - 1990 with
about 2,500 cases per annum.
The main demographic changes noted have been no
decrease in the overall incidence, continuing
decrease in the M:F ratio from 3.6:1 to 2.1:1
and a rise in the mean age at presentation from
63 to 67 yrs. This has led to a prediction
that by 2005 40% of all cases in Britain will
be in patients over 75 years. Lung cancer will
continue to be concentrated amongst patients in
the lower socio-economic groupings. Overall
histological confirmation rate has risen from
41 to 61%, and hence the number of SCLC cases
by 58% to approx 300 per annum. Adenocarcinoma
now accounts for 9% of all cases, a 134% rise
in 15 years.
Treatment analysis shows an unchanged surgical
rate of 10% but a similar outcome (45% survival
at 2 years],. now independent of a9e.
Surprisingly, only 43% of SCLC receive
chemotherapy. This data has been confirmed in
a recent study from Scotland. The reason is
unknown. Marked age gradient for diagnosis and
treatment continues, for patients <60 and >75
years. Histological confirmation is 82% [40%],
and for active treatment 70% (20%].
Conclusion:
Analysis of population-based studies on the
presentation and management of patients with
lung cancer allows conclusions to be drawn
about optimising di4gnostic and management
strategies, which siikq1e institution or trial
data cannot do.
SP22 ORDERING GENETIC CHANGES IN LUNG CANCER DEVELOPMENT P H Rabbitts and
G T Y Chung, MRC Centre, Hills Road, Cambridge CB2 2QH
Epidemiological evidence suggests that the pre-
malignant stage of lung tumour formation is often indolent
providing ample opportunity for clinical intervention.
Unfortunately this stage is almost always asymptomatic and
thus methods need to be devised for its detection.
Bronchial epithelial dysplasia is believed to represent the
pre-neoplastic phase of lung cancer development. The
discovery that this pre-neoplastic stage shares somatic
genetic changes in common with fully malignant disease has
indicated the basis for a new approach to the early detection
of lung cancer. However, a detailed description of the
pathway of genetic changes underlying tumour formation is
required in order to determine which somatic genetic
changes will be the best markers for early disease detection.
To study this molecular progression we analysed a
series of pre-malignant bronchial lesions representing
different stages in lung tumorigenesis and present evidence
that genetic loss on chromosome 3 precedes mutation within
the p53 gene and that genetic damage to chromosome 3 is
not complete in one step but is itself sequential. In addition
a clonal relationship between dysplasia and tumour was
demonstrated by tracing a p53 mutation, detected in a few
cells in the early lesion to the fully malignant tumour.
SP24 CIHEMOTHERAPY INNONSMALL CELL
LUNG CANCER (NSCLC) NThatcher, GJayson, M
Ranson, S Ming Leeand H Anderson CRC DepanmentofMedicalOncology
Christie andWythenshawe Hospitals ManchesterMM4BX
Less than 30% ofNSCLCpatients presentwith tumourwhere
surgery orradicalradiotherapy with curativeintentisthetreatmentof
choice. Moreeffectivechemotherapy offers an avenue ofprogress
butishamperedby traditionalviews thatchemotherapy is
unacceptably toxic, andiswithoutsurvival advantage. Until recently
few active agents, ifosfamide, cisplatin, mitomycin C, vindesine
(>15% OR) hadbeen identified. Recently anumbera new active
agents, gemcitabine, taxanes, topoisomerase I inhibitors , vinorelbine
have in morerigorous evaluation been shown to be effective [1].
Gemcitabine anewpyrimidine antimetabolite isofparticularinterest
in having avery favourabletoxicityprofile. Combinations ofthese
new and older agents arenow beingexamined inphase II andvery
recently inphase mtrials.
Advanced stage. mB /IVdisease:
Chemotherapy using olderagentsie. nonplatinumcontaining
alkylating therapyin general showedno benefitinrandomisedtrials
overbestsupportive care which includedpalliativeradiotherapy.
However, morerecenttrialshaverevealedsignificant survival benefit
in amajority ofstudies [1]. The mostrecentmeta-analysis has again
indicated survival benefit whenchemotherapy wasaddedto best
supportivecare inthepalliative setting [2]. These datareflect -a
subpopulation ofpatients whosignificantly benefitfromthe addition
ofchemotherapy even when objectiveresponserates are only 30% or
less.
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SP25
3-D CONFORMAL RADIOTHERAPY FOR
LUNG CANCER,
J.Armstrong,St.Luke 's Hospital,Dublin, Ireland.
Persistent or recurrent thoracic disease occurs in the
majority of lung cancer patients treated with
radiotherapy alone. A major obstacle to increasing
radiation dose,is the inability of conventional
technology to overcome the limitations imposed by normal
tissue tolerance. This may be partially overcome by the
use of 3-DCRT. The pre-clinical evaluation of this
modality demonstrated that it had the technical
potential to enhance the therapeutic ratio. Subsequent
trials of dose escalation have demonstrated feasibility
and reasonable toxicity and promising outcome. The
utilisation of 3-DCRT has represented a major cultural
shift in the methods by which radiotherapy is delivered
for lung cancer. The ICRU 50 recommendations for target
volume definitions will be addressed. These guidelines
can be used to devise methods of target volume
definition for 3-DCRT. The ability of 3-DCRT systems to
devise dose volume histograms allows calculation of
normal tissue complication probabilities. These
calculated probabilities can be used as an objective
method for comparison of candidate treatment plans.
Furthermore they provide exciting opportunities for
predicting complication risks for individual patients.
The the potential for refinement of these models by
incorporation of functional studies will also be
addressed. Finally, potential clinical strategies for
ongoing research will be outlined.
SP27 NEW ENDOCRINE AGENTS. A Howell.
CRCDepartmentofMedicalOncology
Christie Hospital ManchesterM20 4BX
The major areas of current interest in endocrine therapy for breast
cancer are the new antioestrogens and new aromatase inhibitors.
Although assessed first in advanced disease some are being tested in
the adjuvant situation and may well be in line fortesting forprevention
in high risk groups. The major aims of endocrine therapy are to
produce highly effective agents with minimal toxicity and affect
positively, womens general health by producing HRT like effects on
general well being, bones and lipids. The new antioestrogens are
non-steroidal or steroidal. The' non-steroidal compounds are, with
exception ofraloxifene (a benzothiophene), analogues of tamoxifen
with potentially greater antioestrogenic activity in preclinical tests.
The lead compounds are droloxifene, idoxifene and TAT-59 which
appear to have superior antitumour activity in phase II studies than
expected of tamoxifen: phase III data are required to be certain of
benefit. Raloxifene has the advantage of a positive effect on bone
density with minimal uterine effects but its antitumour activity is not
clear. The 'pure' antioestrogen ICI 182780 (Faslodex) lowers tumour
ER and doubles the remission duration of MCF-7 tumours in nude
mice compared with tamoxifen. A small phase II study was
associated with a high response rate, a long duration ofremission and
minimal toxicity inpatients who failed tamoxifen: aphase III study of
Faslodex versus anastrazole is under way. New aromatase inhibitors
are also steroidal and non-steroidal. They have greater potency with
respect to lowering serum oestradiol than the older compounds. The
three major non-steroidal compounds, anastrozole, letrozole and
vorozole, have approximately equal potency. In phase III studies
versus standard endocrine therapies after failure oftamoxifen all show
similar response rates but longer response durations and significant,
or trends towards significant survival advantages with minimal
toxicity. Exemestane, the lead steroidal compound, is non toxic and
effective but no phase Im data are available todate.
SP26 INTRA-TUMOUR ENDOCRINOLOGY, W.R.
Miller, Edinburgh Breast Unit, Western General
Hospital, Edinburgh EH4 2XU, U.K.
Endocrine communication is founded on the concept that a target organ
may be influenced by secreted chemical messengers from another
source. This is classically evident in premenopausal women in whom
ovarian secretion of oestrogen regulates breast development; the
converse principle underpins the benefits of ovarian ablation in the
treatment ofpremenopausal breastcancer. However, in addition to such
distant controls, there is evidence to suggest that, particularly in
postmenopausal women, local hormonal influences are equally
important. The primary basis for this is the observation that tumoural
levels and profiles of steroid hormones, especially oestrogens, differ
from those in the circulation. This phenomenon must involve some
activeprocess - eitherselective concentration and sequestration againsta
concentration gradientorlocal hormone synthesis. Thereisevidence for
both but the relative contribution to the hormoneal environment differs
between individual tumours. For oestrogen synthesis the potential is
present in both mammary adipose tissue and the breast tumour itself
(although there is controversy as to whether stromal orepithelial cells are
the primary site ofproduction) and these may therefore supply cancer
cells with the hormones they require forgrowth. Equallycytokines and
other factors elaborated by tumour cells may induce local oestrogen
synthesis completing a trophic loop. The particular molecules and
second messenger systems involved are incompletely defined, but the
advent of potent, specific inhibitors and their use in experimental
protocols of primary systemic treatment mean that powerful tools are
now available by which this knowledge may be derived and the clinical
relevance ofsuch intra-tumoural endocrinologyconfirned.
SP28 SCOTTISH BREAST CANCER AUDIT. J A DEWAR,
Dept. Radiotherapy & Orncology, Niniewells
Hospital, Dunidee (oni behalf of the
Scottish Catncer Therapy Network).
The populatiorn studies were all niew cases of inlvasive
breast canicer registered in Scotlarnd int 1987 anid 1993,
comprisitng 2148 arid 2549 cases respectively (89% and
97% of eligible cases). Comparitng the two years, the
proportioni matnaged surgically itncreased from 75% to 81%
aind of these, there was ani inicrease itn the % treated
cornservatively (40 to 52%). Only 55%.of these patienits
had post-operative radiotherapy in 1987 (75% ini 1993)
ard the 5 year local recurretnce rate for the irradiated
was 6% of. 25% for the tnorn-irradiated. The % of patietnts
havinig axillary surgery rose from 79% to 90%. Systemic
adjuvatit therapy usage itncreased from 70% to 96% arid for
premetnopausal niode +ve patiernts, the use of chemotherapy
itncreased from 35% to 75%. Factors affectinig the use of
systemic adjuvarit therapy have beetn antalysed. Anialysis
o2 survival for the 1987 patienits showed that it was
influenced by the expected clirnical factors (tnodal
status etc) but also by Health Board of treatmenit (arid
riot surgical caseload). There is some evidernce that
this is correlated with the use of systemic adjuvarit
therapy). The matnagemenit of breast catncer in Scotlanid
has chatnged sigtnificanitly arid has conisiderable workload
implicationis.14 Invited Oral Presentations
SP29 PRIMARY CHEMOTHERAPY FOR OPERABLE
BREAST CANCER. tani E. Smithi, Head of Section of
Medicinie, Royal Marsdeni Hospital, Fulhaim Road,
Lonidoni SW3 6JJ
Primiary (uicoadjuivanit or pre-operative) cheimiothierapy for operable breast
cancer lias conisistently benii shiowvn to achieve objective tumouir regressionis in 70%
or more ofpatienits, with comiiplete clinical remiiissionis in arouinid 15-25%. In a recent
Royal Marsdeni pilot study of 50 patienits inifuisionial ECF chemliothierapy (contilluous
infusionial 5-FU with interitiitenit bolus epinibicin and cisplatini) achieved a 98%
responise rate witli a comiiplete reimiissioni rate of 66%. This suggests that novel
therapies may be more active tlhan conventional, and this lhypotlhesis is being tested
in a miulticenitre randomiised trial (>300 patienits so far accrued), infusionial ECF is
now being comlpared wvitl convenltionial AC (adriamycini, cyclophosphiamiiide). This
trial miay help to aniswcr a key quiestioni in breast canicer dnig developmenlit. Do
differenices in initial responise rate (a short terni surrogate enidpoinit) predict for long
term suirvival beniefit? If so, thei the problemii of long timiiescale for results in
adjuvanit chelicotlerapy trials can be overcomiie anid progress in the introdtiction of
new therapies for early breast canicer cani be made miuiclh illore rapidly.
Chelmiothierapy-related biological chanigcs mliay also be of predictive valuic lhere. We
have recenitly sihowvn a siginificanit increase in apoptotic inidex in 54% of patients
whose tuimiiouirs were samiipled by nieedle biopsy before anid 24 houirs after
chemotherapy, providing the first clinical evidentce that apoptosis is induiced by
clhemiiothierapy i liii huani patienits and fuirtlher patienits are being recruited to see
wlhether cihaniges in apoptosis provide ani early predictor for a response to
chemotherapy.
Primiiary clhemiotlherapy raises inew issuies concerining suibsequient local
treatiiieit. Conivinicinig data exist inidicatinig that the nieed for mastectoiny can be
siginificanitly reduiced ini patienits presenitinig with large breast primaries. Do patients
achievinig comiplete clinical reiissioni to chemliothierapy requiire surgery at all, in
additioti to radical radiotherapy? We are ctirrently addressing tltis question in a pilot
ranidomiiised trial.
Finially, couild primiiary clhemiothierapy liave an inilerent survival advantage
over post-operative adjuvaimt chelotherapy? Several ranidomuised trials are currently
addressing this qiuestion. Resuilts fromii onie suiggest a slighit trenid in favour of
sunrival beniefit for primary clhemiotherapy anid no data so far suggest ami adverse
survival cffect with this approaclh.